The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

Gastroenterology

Volumn 124, Issue 2, 2003, Pages 303-317

  Creed, Francis ^a,d   Fernandes, Lakshmi ^b   Guthrie, Elspeth ^a   Palmer, Stephen ^c   Ratcliffe, Joy ^a   Read, Nicholas ^b   Rigby, Christine ^a   Thompson, David ^a   Tomenson, Barbara ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Sch of Psychiat and Behav Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0037309719     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50055     Document Type: Article

References (42)

1. Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WW, eds. Rome II: the functional gastrointestinal disorders. McLean, VA: Degnon Associates, 2000:351-375.
2. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-1741.
3. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-1580.
4. Drossman DA, Li Z, Toner BB, Diamant NE, Creed FH, Thompson D, Read NW, Babbs C, Barreiro M, Bank L, et al. Functional bowel disorders: a multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995;40:986-995.
5. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988;95:232-241.
6. Berstad A. Today's therapy of functional gastrointestinal disorders - does it help? Eur J Surg Suppl 1998;583:92-97.
7. Guthrie E, Creed FH, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991;100:450-457.
8. Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet 1983;2:589-591.
9. Jackson JL, O'Malley PG, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressants: a meta-analysis. Am J Med 2000;108:65-72.
10. Gralnek IM. Health care utilization and economic issues in irritable bowel syndrome. Eur J Surg Suppl 1998;583:73-76.
11. Wells K. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10.
12. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-anlaysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
13. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychpharmacol 1999;13:136-143.
14. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-283.
15. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45(Suppl II):69-78.
16. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553-559.
17. Meissner JS, Blanchard EB, Malamood HS. Comparison of treatment outcome measures for irritable bowel syndrome. Appl Psychophysiol Biofeedback 1997;22:55-62.
18. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992;5:75-91.
19. Guthrie E. Brief psychotherapy for patients with refractory irritable bowel syndrome. Br J Psychother 1991;8:175-188.
20. World Health Organization. Schedules for clinical assessment in neuropsychiatry. Geneva, Switzerland: Division of Mental Health, 1994.
21. Drossman DA, Talley N, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. A review and recommendations. Ann Intern Med 1995;123:782-794.
22. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): 1. Conceptual framework and item selection. Med Care 1992;30:473-483.
23. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41:2248-2253.
24. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 1995;33:AS64-AS79.
25. Derogatis LR. The SCL-90-R manual-II: scoring, administration and procedures for the SCL-90-R. 2nd ed. Towson, Md: Clinical Psychometric Research, 1992.
26. Beecham J, Knapp N. Costing psychiatric interventions. In: Thornicroft G, Brewin CR, Wing J, eds. Measuring mental health needs. London: Royal College of Psychiatrists, 1992:163-183.
27. Netten A, Dennet J. Unit costs of health and social care. PSSRU: University of Kent, 1998.
28. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. Volume 35. London: The Pharmaceutical Press, 1998.
29. Barber J, Thompson S. Analysis and interpretation of cost data in randomised controlled trials: a review of published studies. BMJ 1998;317:1195-1200.
30. Solas for missing data analysis. Cork, Ireland: Statistical Solutions Ltd.
31. Anderson I, Tomenson B. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta analysis. BMJ 1995;310:1433-1438.
32. Revick DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-1630.
33. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center, 1994.
34. Nash IJ, Curtis LH, Rubin H. Predictors of patient-related physical and mental health 6 months after percutaneous coronary revascularization. Am Heart J 1999;138:422-429.
35. Whitehead WE, Corazziari E, Prizont R, Senior JR, Thompson WG, Veldhuyzen van Zanten SJO. Definition of a responder in clinical trials for functional gastrointestinal disorders: report of a symposium. Gut 1999;45(Suppl II):1178-1179.
36. Perneger T. What's wrong with Bonferroni adjustments? BMJ 1998;316:236-238.
37. Lave JR, Frank RG, Schulbert HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998;55:645-651.
38. Wilson IB, Clean PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59-65.
39. Dickinson LM, deGruy FV III, Dickinson WP, Candib LM. Health-related quality of life and symptom profiles of female survivors of sexual abuse. Arch Fam Med 1999;8:35-43.
40. Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, Peto T, Warrell D, Seagroatt V. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial. BMJ 1996;312:22-26.
41. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl 1996;30:101-108.
42. Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, Guthrie E, Read N, Thompson D. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860-868.